Amid a backdrop of cautious market optimism, companies with significant insider ownership are drawing investor attention. We examine three firms where those closest to the business are putting their money, spanning biotech, advanced semiconductors, and regional banking.
A powerful but uncommon shift in market leadership is underway as small-caps, energy, and value stocks drive gains. While a sign of health, historical parallels to similar 'breadth' events often coincided with economic stress.
After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
Despite crypto market turmoil and mounting unrealized losses, BitMine Immersion Technologies made its largest weekly Ethereum purchase of the year, as Chairman Tom Lee points to a divergence between price action and robust on-chain activity.
Despite sitting on over $6 billion in unrealized losses, publicly-listed crypto firm BitMine Immersion Technologies continues its aggressive accumulation of Ethereum, viewing the price slump as a strategic buying opportunity.
As the Federal Reserve prepares for a potential policy shift in 2026, analysts flag real estate, financials, energy, and consumer discretionary as vulnerable sectors. Structural challenges and changing macroeconomic conditions could pressure performance despite broader market gains.
Shares of Coastal Financial (CCB) have retreated sharply from recent highs, reigniting the debate over the fintech-focused bank's premium valuation. While long-term performance remains strong, current momentum is fading, leaving investors to weigh high growth expectations against traditional valuation metrics.
In a joint diplomatic push, Chile, Brazil, and Mexico have officially submitted former Chilean President Michelle Bachelet's candidacy to become the first woman to lead the United Nations, as the race to succeed Antonio Guterres heats up.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
An AI-driven analysis suggests JPMorgan Chase stock could see a slight decline to around $295 by mid-April, as the banking giant contends with rising operational costs and regulatory uncertainty, despite strong fundamentals and shareholder returns.
After a punishing multi-year slump, materials stocks are showing signs of life in 2026. Dow and LyondellBasell, offering yields of 5% and 10.9% respectively, present a high-risk, high-reward proposition for income investors betting on a sector recovery.
Investment firm Giverny Capital Asset Management reduced its stake in industrial manufacturer AMETEK in Q4 2025, highlighting a disciplined approach to valuation as markets remain captivated by AI narratives. The firm's portfolio underperformed major indices, pressured by its underweight stance in mega-cap technology.
Amid a market obsessed with artificial intelligence, investment firm Giverny Capital reveals a new position in Hawkins, Inc., a specialty chemicals manufacturer. We examine the rationale behind this contrarian bet and what it says about current market dynamics.
As market leadership broadens beyond tech, income-focused investors are turning to high-yield dividend ETFs. Vanguard's suite offers diversified, cost-effective options for building retirement income streams in a changing landscape.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
A wave of insider buying at 908 Devices Inc. has caught the market's attention, signaling potential optimism among those who know the company best. While not a guaranteed predictor, such coordinated activity often precedes significant corporate developments.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
Digital asset funds have recorded a second consecutive week of massive outflows, totaling $1.7 billion, as hawkish Fed signals and geopolitical tensions trigger a defensive shift. While Bitcoin and Ethereum led the retreat, tokenized precious metals emerged as a rare destination for new capital.
